



MATTO New Ventures Showcase 2017

Welcome to the 3rd Annual MATTO New Ventures Showcase – an opportunity to meet with spin-off companies from universities and hospitals that are seeking expansion investment.

This year we have 20 presenting companies that have already raised nearly \$15 million. Each one is looking for additional capital to further their product development, grow their management team and/or support product launch. Our presenters represent the broad diversity of research and industries that make up our ecosystem from new drugs and medical devices, to eHealth and new materials.

We hope you enjoy this opportunity to meet these inventor entrepreneurs who represent the very best in our research institutions and will continue to drive the growth of the Massachusetts innovation economy. In addition to funding, our presenters are seeking new team members, along with your advice and expertise. By attending you can be part of the newest and most exciting developments in your fields.

As always, we will host a networking reception at the conclusion of the event so that you can meet with and speak to the researchers and entrepreneurs who interest you most.

We would like to express our sincere gratitude to our conference supporters listed below for their financial assistance as well as to our organizing committee Joel Bresler (Northeastern University), Dan Castro (Partners), Tatiana Demidova-Rrice (Harvard University), Jim Freedman (MIT), Nazita Gamini (Brandeis), Julia Goldberg (MTTC), Todd Keiller (WPI), Amy Miracco (Children's Hospital), Rekha Paleyanda (UMass Lowell), Michal Preminger (Harvard University), and Martin Son (Tufts) for their help in putting together today's program.

Vinit Nijhawan
Co-Chair, MATTO New Ventures Planning
Committee

Dr. Abigail A. Barrow
Co-Chair, MATTO New Ventures Planning
Committee & Director, Massachusetts
Technology Transfer Center

Supporters



CONFERENCE AGENDA

1:00 – 1:30	<p>Registration, Dessert Bar, and Networking</p> <p>Boston Room</p>	
1:30 – 1:45	<p>Welcome</p> <p>Boston Room</p>	
1:45 – 2:45	<p>Company Pitch Presentations - Session One</p>	
	<p>Life Sciences Boston Room</p> <p>iTi Health Kalion Myos Elektrofi, Inc</p>	<p>Health Sciences Lowell Room</p> <p>Lumme Inc Accelera, Inc. Prapela, LLC Food for Sleep</p>
2:45 – 3:15	<p>Coffee Break</p> <p>Boston Room</p>	
3:15 – 4:30	<p>Company Pitch Presentations - Session Two</p>	
	<p>Life Sciences Boston Room</p> <p>SpectraWAVE, Inc. University of New England Obsidio Medical Incorporated Honeycomb Biotechnologies NumberOne, LLC Kantum Bio Inc.</p>	<p>Physical Sciences Lowell Room</p> <p>Kinetic Batteries Open Access Technologies, Inc. Treaty LLC PowerHive LLC CognitEyes Infinite Cooling Inc.</p>
4:30 – 6:30	<p>Networking Reception</p> <p>Boston Room</p>	

Company Profiles

Accelera, Inc.

Contact person: Michael Wing, President

Phone: 207-329-1080

Email: Info@accelera.us

Technology from: Harvard University

Company Overview

Our core platform technology is Stochastic Resonance Stimulation (SRS) developed to benefit individuals seeking to improve their balance and physical performance or for individuals needing to improve functional stability while recovering from a joint injury. ACCELERA is developing and will commercialize a lightweight SRS-embedded Ankle Sleeve as its first product and followed by wearable devices for the knee, back, shoulder, wrist/elbow, elderly balance and more. ACCELERA was formed as a result of interest in building a company and in bringing a novel technology to market which would have a broad market appeal as well as provide a much needed solution to improving lives. The team became aware of this SRS technology which was being further developed at the WYSS Institute. The founders who have a great deal of entrepreneurship and management experience have taken great care to organize and secure a team that can successfully develop, commercialize and scale up the business. Our management, board oversight, finance, engineering, manufacturing, business development, clinical research and more are in place.

CognitEyes

Contact person: Addison Mayberry, Graduate Student Researcher

Phone: 775-217-1151

Email: amayberr@cs.umass.edu

Technology from: University of Massachusetts Amherst

Company Overview

CognitEyes offers affordable, lightweight smart glasses that allow players to refine their game by training their eye movements. Our glasses record the player's entire field of view and track their specific gaze point in real time. This enables analysis of why players make the mistakes that they make by giving insight into how they process a situation. Players and their trainers can view the recording after play in order to identify problems at the level of thought and attention based on what the player was looking at, or the video could be streamed live to a tablet for on-the-fly training and assistance. Our eventual goal is to leverage the same technology for use in other markets, including: military training, assistive and safety devices, as well as healthcare - a first use in healthcare being concussion analysis of athletes. Our first product is targeted at the sports market due to market size and level of interest. Current team members: Addison Mayberry is a PhD candidate in the College of Computer and Information Sciences at UMass Amherst. He specializes in the development and testing of low-power eye tracking technology. Deepak Ganesan is a Professor in the College of Computer and Information Sciences at UMass Amherst. Prof. Ganesan's lab focuses on low-power wearable technology as well as mobile health and analytics. He is also the co-founder of Lumme, Inc.

Elektrofi, Inc

Contact person: Jason Norris, Co-founder

Phone: 704-604-8585

Email: Jason@elektrofi.com

Website: www.elektrofi.com

Technology from: MIT

Company Overview

At Elektrofi, we're revolutionizing the delivery of biologics with the intent of improving patients' lives. We're taking biologics (which represent 7 of the top 10 selling drugs in the US) and specifically monoclonal antibodies from a multi-hour IV infusion to subcutaneous delivery. Our proprietary Elektroject formulation technology was borne from one of our cofounders expertise in propulsion technology for cube satellites in low earth orbit. Our core formulation technology allows us to formulate monoclonal antibodies for biopharma companies. We're currently a team of 9 individuals with 5 of the team members having their PhD's and 2 having advanced degrees from MIT. The management team consists of Chase Coffman (MIT PhD in Space Propulsion); Jason Norris (MBA from MIT, former Managing Director of Consortium Capital, Board Member of NVBots and Digital Alloys) and Daniel Dadon (MIT PhD in Biology, Evelo Biosciences, Biogen). We also have an outstanding Board of Advisors that includes 3 MIT professors along with some of the world's foremost experts on our underlying technology.

Food for Sleep

Contact person: Bob Jones, CEO & Founder

Phone: 617-697-1163

Email: bobjones@foodforsleep.com

Website: www.foodforsleep.com

Technology from: Harvard Medical School/Beth Israel

Company Overview

We create consumer products that meet health needs, using nutrition rather than drugs. Our approach is to identify an unmet health need that consumers will pay to meet, mine the clinical publications for proven technologies that will meet the need, and then commercialize the technology. Our current focus is "better performance and better recovery through better sleep." Food for Sleep is the first product offered by Scientific Nutrition Products, Inc. Food for Sleep is just foods, which means no side effects, no hangover, and no prescription required. After "sleep," our next target will be "cognitive health," probably called "Food for Thought™." Our scientific advisors help us develop formulations (supported by clinical trials) that address our target conditions. They include faculty members at Harvard Medical School, with deep expertise in clinical nutrition. Working with target customers, we develop those formulations into consumer products for retail sales. Our founder has two decades of experience launching products and building companies in this arena. He has sold products through every major pharmacy chain, grocery chain and Wal*Mart in the country. His expertise is primarily in identifying market needs, customer segmentation, product positioning, and route to market.

Honeycomb Biotechnologies

Contact person: Jim Flanigon, Co-founder & CEO

Phone: 508-308-6254

Email: jflanigon@honeycomb.bio

Website: www.honeycomb.bio

Technology from: MIT

Company Overview

Honeycomb makes single-cell multi-omic technologies for biomedical research, immune-based diagnostics, and quality control of cellular medicines. Founded on pioneering technology from MIT, our Hive Array platform enables single-cell interrogation of RNA, proteins, tissue micro-environments, and cellular function—all in a scalable, portable, and cost-effective manner. Single-cell technologies are key to ‘cracking the code’ for personalized therapies—which patients are likely to respond and why. Our core single-cell profiling platform helps solve these questions by integrating: On-site sample capture, Multi-omic single-cell readout, Precious sample single-cell storage. Our founders are a combination of successful life science & technology entrepreneurs, and world-renowned thought leaders in the single-cell, immunology, and biotechnology engineering: Jim Flanigon, PhD, MBA (CEO) Proven biotechnology entrepreneur, with executive and engineering roles at Genzyme, Akamai and Oracle; Todd Gierahn, PhD (CSO) Lead engineer of Honeycomb technology at MIT. Developed foundational platform for Genocea Biosciences; J. Christopher Love, PhD (MIT) Associate Professor of Chemical Engineering. Expert on single-cell technologies that reveal immunological features within chronic diseases; and Alex K. Shalek, PhD (MIT) Assistant Professor of IMES & Chemistry. Focus on development of new technologies for deep, integrated molecular profiling of cells and their interactions.

Infinite Cooling Inc.

Contact person: Karim Khalil, Co-Founder & CTO

Phone: 908-342-4545

Email: karim@infinite-cooling.com

Website: www.infinite-cooling.com

Technology from: MIT

Company Overview

Infinite Cooling's mission is to provide novel technology to enable water-sustainable thermoelectric power. According to studies by the UN and the US State Department, we are on the path to an extreme freshwater shortage by 2030. Power plants are the US's largest water consumer - power plants use 139 billion gallons of freshwater per day, 50% of total US freshwater withdrawals. Power plants typically use evaporative cooling, where a portion of the water is evaporated to cool the remaining water. The vapor is released into the atmosphere, where it forms a plume. New water needs to be frequently added to the cooling system to account for the lost water vapor. The system's remaining water becomes more concentrated in salts and pollutants and needs to be treated, at an additional cost. A single 250MW power plant will consume the same amount of water as 100,000 residential users and spend \$5M/year on water alone. Infinite Cooling core technology can help power plants produce reliable electricity while using significantly less water. Infinite Cooling's management consists of multiple PhD's from MIT in Mechanical Engineering and minors in Business from the MIT Sloan School.

iTi Health

Contact person: Kim Kelly, CEO & CSO

Phone: 434-249-0344

Email: kkelly@itihealth.com

Website: www.itihealth.com

Technology from: Massachusetts General Hospital

Company Overview

iTi Health's lead technology is centered on the novel target plectin-1. Plectin-1 is an extensively validated marker of pancreatic cancer with robust expression in 11 human tumors tested. In pancreatic cancer, esophageal, head and neck squamous cell and ovarian cancers, as well as in a growing list of additional malignancies, plectin is mis-expressed on the cell surface where it is accessible to our proprietary plectin-targeting agents. Kim Kelly, PhD CEO and CSO has 17 years in phage display innovation and imaging agent discovery and development (Utah, MGH, UVA). Discovered Plectin-1 biomarker with NIH funding, multiple NIH-R01 funded programs as well as industrial collaborations. Colin M Rolph CFO is the Managing Director of Tall Oaks Capital, LP and is also the CFO of two other UVA startups, EpiEP, Inc. and TearSolutions Inc.. Mr Rolph has been working with venture startups for the past 17 years. Julien Dimastromatteo, PhD Principal Scientific Officer Instructor of Research, UVA Experienced in radiotracer development. Robert Lutz, PhD has 25+ years in biotech R&D. He was the Principal consultant at Crescendo BioPharma Consulting and the former VP, Translational Research and Development at ImmunoGen. Michelle Higgin, PhD, Principal PharmaDirections. She has 20+ years in pharmaceutical R&D. and a PhD in Biochemistry. PharmaDirections, Inc is the leading CRO in virtual drug development, assisting with strategic planning and project management.

Kalion

Contact person: Darcy Prather, President

Phone: 240-988-8011

Email: darcy@kalioninc.com

Website: www.kalioninc.com

Technology from: MIT

Company Overview

Kalion is an early stage industrial biotech company providing low-cost access to high-purity glucaric acid, glucuronic and other chemicals using traditional, green, fermentation technology. Glucaric acid needs to be of high purity to address pharmaceutical needs. In polymer applications glucaric acid must be both high purity and low cost. Our fermentation pathway allows us to immediately address the high purity needs of the high value pharmaceutical markets. Our pathway also allows us to address other high value nutraceutical applications including glucuronic acid and myo-inositol in energy drinks. Lastly, we will produce low-cost high-purity glucaric acid for the billion-dollar polymer markets. Darcy Prather, a Rhodes Scholar, who focused on new product issues at McKinsey, will guide the business. Prof. Kristala Jones Prather of MIT's Chemical Engineering Department will serve as an advisor. Dr. Steve Van Dien guides the commercialization process. Dr. Van Dien was a key contributor to the scale up bio-BDO while he worked at Genomatica. He took bio-BDO from lab scale to a \$100 million facility. Dr. Alan Watson, who has work extensively in pharma and with startups, is VP Business Development.

Kantum Bio

Contact person: Jean-Francois Carbonneau, Interim CEO

Phone: 240-988-8011

Email: jgcarbonneau@kantumresearch.com

Website: www.kantumdx.com

Technology from: Partners Healthcare/MGH

Company Overview

Acute Kidney Injury (AKI) kills more people each year than diabetes, breast cancer, prostate cancer, and heart failure combined. These lives are lost because physicians have no early biomarker and no therapy for AKI. Kantum Bio has identified UDP-glucose (UDP-G) as an early biomarker for AKI. Kantum Bio has also identified a molecule that can be developed into a new drug for AKI. We will finalize and commercialize an advanced diagnostic test and therapy for AKI. Our Main Value Proposition: "Learn about the onset of AKI early, and treat/prevent this deadly complication". The Company currently has four executives: Jean-Francois Carbonneau (CEO) cumulates an extensive entrepreneurial experience; Dr. Sylvie Breton (CSO) Professor at Harvard Medical School is internationally recognized as a kidney physiology specialist; Dr. Patrick Yeramian (CMO) has over 25 years in drug development and clinical trials; and David Giddings (CBO) is former COO of Boehringer Mannheim Corporation and former CEO of Diametrics Medical, a NASDAQ traded company.

Kinetic Batteries

Contact person: Aaron Birt, Co-founder & CEO

Phone: 717-602-5158

Email: aaron.birt@kinetic-batteries.com

Website: www.kinetic-batteries.com

Technology from: Worcester Polytechnic Institute

Company Overview

Kinetic Batteries (KB) is developing a next generation lithium ion battery manufacturing line that is cheaper and greener than the tape casting lines used today. Tape casting is a 30 year old technology that utilizes toxic solvents that must be nearly 100% recycled to meet environmental regulations. To eliminate the solvent from the electrode, hundreds of meters of furnaces are required. The result is an expensive and energy intensive manufacturing process. KB solves this by preparing a dry, powdered feedstock with a patent pending blending technique, and eliminates the need for post-processing by applying the powders with a process called cold spray. KB will bring this technology to market with its strategic partners by licensing first to niche battery manufacturers and then to major manufacturers such as Samsung or Panasonic. KB's management team has backgrounds encompassing all key aspects of the business. Dr. Aaron Birt is co-founder of KB, has a PhD in materials science from WPI, and is an expert in powder metallurgy and cold spray processing. Professor Diran Apelian is co-founder of KB and expert in strategy and business development. KB's battery expert is a WPI alum with a focus on cell design and testing.

Lumme Inc

Contact person: Akshaya Shanmugam, CEO

Phone: 413-362-4080

Email: akshaya@lumme-labs.com

Website: <https://lumme-labs.com>

Technology from: University of Massachusetts Amherst

Company Overview

Lumme's mission is to solve the nation's \$800B addiction problem with a software platform that collects big data for health and extracts actionable intelligence. Our proprietary software platform automatically predicts addictive behavior by leveraging contextual cues & delivers just-in-time interventions. Our current products focus on smoking cessation, alcohol addiction, & obesity. Lumme is funded by the National Institutes of Health & is an outcome of research conducted at UMass Amherst & Yale Medical School. Lumme's founding members are domain experts in addiction & health tech. Dr. Shanmugam combines her PhD in engineering & entrepreneurial experience to lead the company. Lumme's technology is an extension of Dr. Parate's PhD research at UMass Amherst. This lab is led by Lumme's co-founder, Dr. Ganesan, who is also the thrust lead on NIH's mHealth center. Our other co-founder, Dr. McKee from Yale School of Medicine is the nation's leading expert in addiction and is the director of the Yale Tobacco Treatment Clinic.

Myos

Contact person: Richard Horgan, CEO

Phone: 607-215-6401

Email: rhorgan@mba2018.hbs.edu

Technology from: Boston Children's Hospital

Company Overview

The vision for Myos is to commercialize a cell-therapy treatment for patients with Duchenne muscular dystrophy (DMD) – a rare muscle degenerative disease leading to pulmonary and cardiac failure between the age of 25-30. Myos is working with Boston Children's to identify and use genes responsible for engraftment and fusion to enable muscle regeneration for patients. By identifying these genes, we will deliver "healthy" cells to the patient to enable muscle regeneration. Currently, our plan is to correct cells ex-vivo to avoid immuno-rejection while replenishing the body with healthy muscle cells. Once we develop the proof-of-concept for the therapeutic, we will partner with a well-established biotechnology/pharmaceutical company for human trials and downstream processes. The product will be a therapeutic. The startup is supported by a strong team. Founder and SAB-member, Louis Kunkel, is world-renown for his discovery and cloning of the dystrophin gene. Prof. Kunkel's career has been successfully dedicated to furthering the understanding and treatment for Duchenne's. Prof. Kunkel's post-doc and founding member, Dr. Angela Lek, is regarded for her work on the cellular and genetic pathways underlying Facioscapulohumeral Dystrophy. Lastly, founding member Rich Horgan is a Harvard MBA and has significant experience with launching new products and businesses.

NumberOne, LLC

Contact person: Carlos Estrada, Associate Prof of Surgery & Jeanne Chow, Associate Professor of Radiology, Harvard Medical School

Phone: 617-935-4350

Email: carlos.estrada@childrens.harvard.edu and Jeanne.chow@childrens.harvard.edu

Technology from: Boston Children's Hospital

Company Overview

At NumberOne our vision is to help as many people as possible who suffer from, or who are at risk of developing, urinary incontinence (UI) by bringing non-invasive and personalized pelvic floor muscle therapy (PFMT, AKA biofeedback therapy) to patients' homes. Our core technology allows "smart" Kegel exercises with a novel dual sensor pad that 1) quantifies the degree of UI, and 2) measures strength of the pelvic muscles. Our planned product includes 3 components: disposable dual sensor pads, a durable microprocessor/Bluetooth radio module, and an app that guides users through PFMT and tracks their progress. Our co-founders, Carlos Estrada, MD, MBA, and Jeanne Chow, MD, have been developing their product for almost 2 years. Dr. Estrada is a pediatric urologist who directs the urodynamics and neurourology program at Boston Children's Hospital (BCH). He was responsible for establishing and growing the in-hospital PFMT program at BCH. He recently earned an MBA from the MIT Sloan School of Management. Dr. Chow is a pediatric radiologist, and is the director of uroradiology at BCH. Through state-of-the-art imaging of complex urological patients, she has a unique perspective on pelvic floor muscle anatomy and function.

Obsidio Medical Inc.

Contact person: Alan Braly, Co-founder & CEO

Phone: 612-210-6050

Email: alan.braly@obsidiomedical.com

Website: www.obsidiomedical.com

Technology from: Brigham & Women's Hospital and MIT

Company Overview

Obsidio Medical's mission is restoring health and extending life by stopping undesirable flow in vessels anywhere in the body. The company was founded to commercialize a novel biomaterial technology platform developed at Brigham & Women's Hospital and MIT that eliminates trade-offs between efficacy and deliverability that are inherent in existing interventional devices. The platform is a unique, patent-pending hydrogel with properties allowing a solid to be easily injected through catheters, enabling rapid and effective performance in a range of interventional applications. Our founding team combines extensive clinical, technical, and commercial expertise: Alan Braly, MBA, SM – Leads day-to-day operations of Obsidio Medical as CEO, previously Director at Health Advances, a healthcare consulting firm, and in R&D at Medtronic focused on biomaterial vascular devices; Dr. Rahmi Oklu, MD, PhD – Acting Chief Medical Officer, co-inventor of platform, professor of Vascular Interventional Radiology at Mayo Clinic, expert in interventional vascular procedures; Dr. Ali Khademhosseini, PhD – co-inventor of platform; professor of Medicine at Harvard Medical School, expert in biomaterials for medical applications; Dr. Robert Langer, ScD – Institute Professor at MIT, pioneer in biomaterials, drug delivery, and tissue engineering, extensive record of translational research and entrepreneurship across many successful startups.

Open Access Technologies, Inc.

Contact person: Howard Berke, President & CEO

Phone: 603-821-9245

Email: Howard.berke@openaccesstech.com

Technology from: University of Massachusetts Lowell

Company Overview

Open Access Technologies, Inc. (OAT) is a spin out from UMass Lowell and under exclusive copyright license. Enable PDF business sector is a spinout from The Paciello Group (TPG), Nashua, NH (previously cofounded by Mike Paciello and Howard Berke) which was recently acquired by Vector Capital (VFO). OAT is transforming complex and dynamic data visualizations into intelligent, voice-enabled interfaces. OAT's products are - Weave Access TM- First to market ADA compliant business intelligence; Enable Viz TM- Best in class modular toolkit for accessible visualization; and EnablePDF - Fully automated SAAS platform for accessible remediation PDF. Team: Michael Paciello (Chairman, Co-Founder); TPG CEO/Founder, world renown accessibility visionary and technologist; William Walker (VP Product), 30 years of experience in software engineering, leadership, and open source at several Fortune 500 companies; Becky Gibson (Dir. of Product Development), IBM Software Architect with 30+ years of diverse experience in IBM corporate and open source development; Marsha Matzkin (Controller, Admin, Finance, part-time), 25 years of financial management experience, Controller and VP Finance; Edwin Miller, (Corporate Counsel), Partner at Sullivan & Worcester, 35 years of experience in IPO, M&A, Investor and corporate representation.; David Rickerby, (Technology / IP Counsel), Founder at Boston Technology Law, 20 years of experience in technology licensing and IP law.

PowerHive LLC

Contact person: Weijia Tao, CEO

Phone: 508- 723- 6370

Email: kirito1912@gmail.com

Technology from: Worcester Polytechnic Institute

Company Overview

Our vision is to provide safe, affordable, and accessible robotic solutions to common problems in everyday tasks. We believe people should never have to do mundane repetitive tasks. The core technologies in our company are in soft robotics (including soft actuation, sensing, and control) and origami robotics and devices (including origami-inspired mobile robots, manipulators and tools). Our technologies offer lower cost, higher safety, faster manufacturing speeds than traditional robots and devices. Our focus in the first 2 years is on a new soft robotic gripper for e-commerce fulfillment, warehouse automation, bakery/produce packaging services. We have a number of patents that cover this technology and its extensions. Our team is formed by 4 people leading R&D, operations, and marketing. We are honored to have Ms. Weijia Tao as our CEO. She received her MS degree from WPI, Robotics (RBE) Program in 2017. Dr. Cagdas Onal is our CSO. He is currently an Assistant Professor in WPI ME Department. He obtained his PhD degree from CMU in 2009. Dr. Ming Luo is our CTO. He obtained his PhD degree from WPI RBE in 2017. Ms. Dou Dou takes charge of Marketing and Sales. Dou is currently pursuing her MS in Marketing.

Prapela, LLC

Contact person: John Konsin, Co-founder & CEO

Phone: 978-760-4988

Email: JohnKonsin@prapela.com

Website: www.prapela.com

Technology from: Wyss Institute at Harvard University

Company Overview

Prapela's strategic intent is to stimulate health with affordable medical device and consumer products for infants and caregivers. Our core competency is the application of Stochastic Vibrotactile Stimulation or SVS to improve infant health. Our first product, the \$150 Prapela SVS baby box features our gentle, stochastic vibration which helps infants relax, breathe and sleep. In the consumer market, the product will target parents and infants struggling with colic. In the medical market, our SVS box will help newborns with single ventricle heart disease during their Interstage period and drug-exposed newborns and their caregivers in the hospital and at home. Prapela's founding team consists of our Scientific Advisor, the inventor of SVS for infants, who is currently Chair of Neurology at a leading teaching hospital. Our CTO spent 7 years developing the product at Harvard's Wyss Institute and 25 years in R&D. Our CEO has 37 years in consumer and medical devices and has led or assisted in the launch of over 100 medical products. We have 3 advisors – a pioneer in the use of social media to build grass roots support for products, another with 10 years communications experience, and a manufacturing advisor with 30 years in medical devices.

SpectraWAVE, Inc.

Contact person: James Muller, CEO

Phone: 617-717-8570

Email: James.muller19@gmail.com

Website: www.spectrawave.com

Technology from: Partners Healthcare

Company Overview

SpectraWAVE, Inc is a medical device start-up that will improve care for coronary artery disease, the world's leading cause of death. It will address two unmet needs of cardiac patients by designing a multimodality OCT-spectroscopy coronary catheter-based diagnostic instrument. In the three years following stenting approximately 5% of patients experience complications at the stented site and approximately 10% develop a second coronary event resulting from disease at another location in the artery. The OCT feature of the new device will improve outcomes at the stented site; the spectroscopy feature will give a profile of plaques in other parts of the coronary tree and facilitate improved local and systemic preventive therapy. The Board of SpectraWAVE includes expertise in the areas needed for this endeavor: Dr. James Muller initiated the field of research on vulnerable coronary plaques and founded the first intracoronary spectroscopy company, Dr. Gregg Stone, is a world-renowned interventional cardiology researcher and leads large clinical outcomes trials of OCT and spectroscopy, Dr. Gary Tearney is the founder of OCT, and Jeff O'Donnell is an experienced business leader who has led 6 successful medical device start-ups. Engineers experienced in OCT and NIRS have been hired, an office started, and plans to assemble the product have been made.

Treaty LLC

Contact person: Marc Gammell, CEO

Phone: 774-644-1276

Email: marcgammell@treatyllc.com

Website: www.treatyllc.com

Technology from: University of Massachusetts Amherst

Company Overview

Our company, Treaty LLC, is a start-up biotech company out of UMass Amherst. We make new products and technology with advanced biomaterials. The products and technology we have made so far has come from our work with a biopolymer called nanocellulose. The first product we created is a biodegradable anti-fog solution called FogKicker. FogKicker uses nanocellulose's hydrophilic property to prevent fog; it can be coated on any surface to prevent fog, including glasses, goggles, bathroom mirrors, and car windshields. Our vision is to continue developing commercial products to attract broader markets of other sports and public use where fogging is a common phenomenon. The formula has been proven to be the most effective as well as only green product among competitors/available solutions. Parallely we are actively involved in proving the medical use of the formula through clinical trials which will solve the fogging problem for endoscopic and laparoscopic surgery. This is an opportunity to impact human lives and medical outcomes. Treaty LLC was founded by Yinyong Li, Kenneth R. Carter, and Marc Gammell. Li is acting Chief Technical Officer, Carter is Chief Scientific Advisor, and Gammell is Chief Executive Officer.

University of New England

Contact person: Srinidi Mohan, Assistant Professor

Phone: 207-221-4058

Email: smohan@une.edu

Website: <http://www.une.edu/people/srinidi-mohan>

Company Overview

The soon to be formed company will provide a novel less-invasive blood based assay to assess and monitor an aggressive breast tumor, namely, estrogen-negative breast cancer (that includes triple-negative breast cancer subtype). Estrogen-negative breast cancer affects about 60,000 patients each year, in the U.S alone. Currently no reliable blood-based marker exists for early stage estrogen-negative prognosis and/or disease progression monitoring. To help improve estrogen-negative disease prognosis and treatment effectiveness measurement, we have developed a simple, yet sensitive, reliable and ethnically selective assay that would benefit early cancer diagnosis, and will be a cost-effective alternative to traditional assays for neoadjuvant treatment management.

Notes:



Thank you to our Supporters



www.Chapin-IP-Law.com



www.c-m.com



www.gtlaw.com



www.LALaw.com



www.bioinc.org



www.pepperlaw.com



www.princelobel.com



www.wilmerhale.com

WILMER CUTLER PICKERING HALE AND DORR LLP